Literature DB >> 17875947

Greater inhibition of platelet aggregation and reduced response variability with prasugrel versus clopidogrel: an integrated analysis.

Govinda J Weerakkody1, Joseph A Jakubowski, John T Brandt, Christopher D Payne, Hideo Naganuma, Kenneth J Winters.   

Abstract

Multiple studies report response variability to a 300-mg clopidogrel loading dose (LD). Pooled platelet aggregometry data compared responses (change in maximal platelet aggregation [DeltaMPA] or inhibition of platelet aggregation [IPA]) to clopidogrel 300-mg (n = 131) or prasugrel 60-mg (n = 109) LDs. Poor responder rates were determined using empiric criteria (IPA < 10% and DeltaMPA < 10% for 20 microM and 5 microM adenosine diphosphate [ADP]) and Bayesian model-based criteria (IPA < 20% and DeltaMPA < 15% for 20 microM ADP; IPA < 25% and DeltaMPA < 20% for 5 microM ADP). Prasugrel achieved greater DeltaMPA and IPA from 2 to 24 hours post-LD (P < .001). For 20 microM ADP, poor responder rates for clopidogrel ranged from 17% to 43%; no prasugrel poor responders were observed. Regardless of the criterion, prasugrel 60 mg achieved greater IPA and fewer poor responders than the clopidogrel 300-mg LD.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17875947     DOI: 10.1177/1074248407304731

Source DB:  PubMed          Journal:  J Cardiovasc Pharmacol Ther        ISSN: 1074-2484            Impact factor:   2.457


  5 in total

Review 1.  Monitoring the effectiveness of antiplatelet therapy: opportunities and limitations.

Authors:  Nalyaka Sambu; Nick Curzen
Journal:  Br J Clin Pharmacol       Date:  2011-10       Impact factor: 4.335

2.  Effect of grapefruit juice on the bioactivation of prasugrel.

Authors:  Mikko T Holmberg; Aleksi Tornio; Hanna Hyvärinen; Mikko Neuvonen; Pertti J Neuvonen; Janne T Backman; Mikko Niemi
Journal:  Br J Clin Pharmacol       Date:  2015-06-01       Impact factor: 4.335

3.  Considerable variability in platelet activity among patients with coronary artery disease in response to an increased maintenance dose of clopidogrel.

Authors:  Julie H Oestreich; John Holt; Steven P Dunn; Susan S Smyth; Charles L Campbell; Richard Charnigo; Wendell S Akers; Steven R Steinhubl
Journal:  Coron Artery Dis       Date:  2009-05       Impact factor: 1.439

Review 4.  Comparison of prasugrel and clopidogrel in patients with acute coronary syndrome undergoing percutaneous coronary intervention.

Authors:  Nicholas B Norgard; Mazen Abu-Fadel
Journal:  Vasc Health Risk Manag       Date:  2009-11-02

5.  [Evaluation of treatment adaptation for low response to ASA in vascular surgery].

Authors:  T Hummel; S H Meves; A Breuer-Kaiser; J O Düsterwald; D Mühlberger; A Mumme; H Neubauer
Journal:  Chirurg       Date:  2021-07       Impact factor: 0.955

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.